Cefalexin (Keflex) Dosing in ESRD Requires Significant Dose Reduction and Extended Intervals
For adult patients with end-stage renal disease (ESRD) on hemodialysis, cefalexin should be dosed at 250-500 mg every 12-24 hours, with doses administered after dialysis sessions. 1, 2
Pharmacokinetic Rationale for Dose Adjustment
Cefalexin is primarily eliminated by the kidneys (70-100% excreted unchanged in urine within 6-8 hours in patients with normal renal function), making dose adjustment essential in ESRD 3. In anephric patients, the serum half-life increases dramatically from approximately 1 hour in normal subjects to 8.47 hours when creatinine clearance approaches zero 2. This prolonged half-life necessitates both dose reduction and interval extension to prevent drug accumulation and potential toxicity.
Specific Dosing Recommendations
For Patients on Hemodialysis
- Loading dose: 250-500 mg orally 1
- Maintenance dose: 250-500 mg every 12-24 hours 1
- Timing: Administer doses after hemodialysis on dialysis days 2, 4
The rationale for post-dialysis dosing is that hemodialysis removes approximately 58% of serum cefalexin over a 6-hour dialysis session 4. Administering the dose after dialysis prevents premature drug removal and ensures adequate therapeutic levels.
Dosing Algorithm Based on Creatinine Clearance
For patients with creatinine clearance <30 mL/min (which includes ESRD patients), the dosing interval should be extended proportionally to the degree of renal impairment 3. The correlation between elimination rate constant and creatinine clearance has been established: Ke = 0.0766 + 0.0060 × CrCl 2.
Important Clinical Considerations
Absorption Variability in ESRD
A critical pitfall: In anephric patients, peak cefalexin levels may be delayed significantly—in some cases reaching peak concentrations at 6-12 hours rather than the typical 1-2 hours due to delayed absorption 4. This delayed absorption pattern occurred in 2 of 6 anephric patients studied, highlighting the need for clinical monitoring rather than assuming predictable pharmacokinetics.
Adequate Urinary Concentrations Despite Renal Impairment
Even in patients with impaired renal function, urinary concentrations of cefalexin remain adequate (500-1000 mcg/mL) for treating most urinary tract infections caused by E. coli, Klebsiella, and Proteus mirabilis 4, 3. This makes cefalexin a viable option for UTI treatment in ESRD patients, though systemic infections may require alternative agents.
Monitoring Parameters
- Baseline assessment: Serum creatinine and creatinine clearance determination 3
- Ongoing monitoring: Watch for signs of drug accumulation (CNS effects, gastrointestinal symptoms) 5
- Dialysis schedule: Coordinate dosing with hemodialysis sessions to optimize drug levels 2
Contraindications and Cautions
The standard adult dosage range of 1-4 g daily in divided doses 5 is not appropriate for ESRD patients. Using normal dosing in ESRD will result in excessive drug accumulation and increased risk of adverse effects. The dose reduction should be proportional to the reduced creatinine clearance 3.
Alternative Considerations
For severe infections requiring higher doses, parenteral cephalosporins with appropriate renal dosing adjustments should be considered rather than attempting to escalate oral cefalexin doses beyond recommended limits in ESRD 5.